Bellmunt et al identified factors associated with a worse prognsosis for a patient with metastatic transitional cell carcinoma that is resistant to platinum-based chemotherapy. These can help to identify patients who may benefit from more aggressive or a novel therapy. The authors are from multiple institutions in Europe and North America.
Patient selection: metastatic transitional cell carcinoma of the urothelial tract
Parameters:
(1) ECOG performance status
(2) hemoglobin in g/dL
(3) liver metastases
Parameter |
Finding |
Points |
ECOG performance status |
0 |
0 |
|
>= 1 |
1 |
hemoglobin in g/dL |
>= 10 g/dL |
0 |
|
< 10 g/dL |
1 |
liver metastases |
absent |
0 |
|
present |
1 |
number of adverse prognostic factors =
= SUM(points for all 3 parameters)
Interpretation:
• minimum number: 0
• maximum number: 3
• The greater the number the worse the prognosis.
Number of Factors |
Median Overall Survival |
0 |
14.2 months |
1 |
7.3 months |
2 |
3.8 months |
3 |
1.7 months |
Specialty: Hematology Oncology, Surgery, general, Urology
ICD-10: ,